Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$9.98
$0.88
$1.65
$62.85M1.23269,831 shs206,800 shs
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
$21.55
$21.50
$2.31
$21.60
$1.83B-0.691.69 million shsN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$1.07
$1.01
$0.56
$1.43
$65.08M1.75430,375 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00%0.00%0.00%0.00%0.00%
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/AN/AN/AN/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.6819 of 5 stars
0.00.00.04.70.02.50.0
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVROBIO, Inc. stock logo
AVRO
AVROBIO
0.00
N/AN/AN/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.00
N/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/A$2.13 per shareN/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
$2.07M885.53N/AN/A$3.07 per share7.02
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
$30M2.17N/AN/A$0.81 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/A
26.17
26.17
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.21
10.64
10.64
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
N/A
3.60
3.60

Institutional Ownership

CompanyInstitutional Ownership
AVROBIO, Inc. stock logo
AVRO
AVROBIO
62.63%
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
72.85%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
74.01%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
37.21%

Insider Ownership

CompanyInsider Ownership
AVROBIO, Inc. stock logo
AVRO
AVROBIO
9.20%
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
7.75%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
17.00%
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1344.89 million40.76 millionOptionable
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
10185.06 million78.47 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
Surface Oncology, Inc. stock logo
SURF
Surface Oncology
3560.82 million53.53 millionNot Optionable

Recent News About These Companies

Q3 2024 Heron Therapeutics Inc Earnings Call
How wearable tech can help women fight breast cancer

Top Headlines

View All Headlines
AVROBIO stock logo

AVROBIO NASDAQ:AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fusion Pharmaceuticals stock logo

Fusion Pharmaceuticals NASDAQ:FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Surface Oncology stock logo

Surface Oncology NASDAQ:SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.